In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $492.69, indicating a -1.96% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of ...

Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...